Table 1.
Characteristics of patients at enrollment
| TFH lymphomas (n=40, %) | PTCL (n=33, %) | ALCL (n=9, %) | Cutaneous T-cell (n=12, %) | p-value | |
|---|---|---|---|---|---|
| Disease status | |||||
| Newly diagnosed | 31 (77.5) | 25 (75.6) | 7 (77.8) | 10 (83.3) | 0.962 |
| Relapsed or refractory | 9 (22.5) | 8 (24.4) | 2 (22.2) | 2 (16.7) | |
| Diagnosis | |||||
| AITL/FTCL/PTFH | 31/5/4 | - | - | - | - |
| PTCL-NOS/MEITL | - | 29/4 | - | - | - |
| ALK-negative/positive ALCL | - | - | 4/5 | - | - |
| Cutaneous ALCL/SPTCL | - | - | - | 5/3 | - |
| Transformed MF/CTCL | - | - | - | 1/3 | - |
| Age (yr) | |||||
| ≤ 60 | 22 (55.0) | 15 (45.5) | 9 (100) | 10 (83.3) | 0.007 |
| > 60 | 18 (45.0) | 18 (54.5) | 0 ( | 2 (16.7) | |
| Sex | |||||
| Male | 23 (57.5) | 22 (66.7) | 8 (88.9) | 8 (66.7) | 0.348 |
| Female | 17 (42.5) | 11 (33.3) | 1 (11.1) | 4 (33.3) | |
| Serum LDH (n) | |||||
| Normal | 14 (35.0) | 18 (54.5) | 4 (44.4) | 5 (41.7) | 0.419 |
| Increased | 26 (65.0) | 15 (45.5) | 5 (55.6) | 7 (58.3) | |
| Bone marrow involvement (n) | |||||
| Absent | 29 (72.5) | 24 (72.7) | 8 (88.9) | 10 (83.3) | 0.659 |
| Present | 11 (27.5) | 9 (27.3) | 1 (11.1) | 2 (16.7) | |
| Ann Arbor stage (n) | |||||
| I/II | 5 (12.5) | 12 (36.4) | 1 (11.1) | 7 (58.3) | 0.005 |
| III/IV | 35 (87.5) | 21 (63.6) | 8 (88.9) | 5 (41.7) | |
| IPI (n) | |||||
| Low/Low-intermediate risk | 25 (62.5) | 19 (57.6) | 7 (77.8) | 12 (100) | 0.044 |
| High-intermediate/High risk | 15 (37.5) | 14 (42.4) | 2 (22.2) | 0 | |
| Cell-free DNA a) | |||||
| Low (≤ 12.0 ng/dL) | 17 (42.5) | 18 (54.5) | 3 (33.3) | 9 (75.0) | 0.160 |
| High (> 12.0 ng/dL) | 23 (57.5) | 15 (45.5) | 6 (66.7) | 3 (25.0) | |
| ctDNA mutation | |||||
| Not detected | 12 (30.0) | 14 (42.4) | 5 (55.6) | 10 (83.3) | 0.010 |
| Detected | 28 (70.0) | 19 (57.6) | 4 (44.4) | 2 (16.7) | |
AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large cell lymphoma; CTCL, cutaneous T-cell lymphoma; ctDNA, circulating tumor DNA; FTCL, follicular helper T-cell lymphoma; IPI, International Prognostic Index; LDH, lactate dehydrogenase; MEITL, monomorphic epitheliotropic intestinal T-cell lymphoma; MF, mycosis fungoides; PTCL, peripheral T-cell lymphoma; PTCL-NOS, peripheral T-cell lymphoma, not otherwise specified; PTFH, peripheral T-cell lymphoma with TFH phenotype; SPTCL, subcutaneous panniculitis-like T-cell lymphoma; TFH, T follicular helper.
a)
The cutoff value for dichotomization was the median value of 94 patients’ cell-free DNA concentration (12.0 ng/dL).